Related Experiment Video
Updated: Jan 1, 2026

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Changes in Corneal Asphericity after MyoRing Implantation in Moderate and Severe Keratoconus
Masoud Khorrami-Nejad1, Ozra Aghili1, Hesam Hashemian2
1Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Purpose:
To evaluate the effect of MyoRing implantation on corneal asphericity in moderate and severe keratoconus (KCN).
Methods:
This cross-sectional observational study comprised 32 eyes of 28 patients with KCN, who had femtosecond-assisted MyoRing corneal implantation. The primary outcome measures were preoperative and six-month postoperative corneal asphericity in 6-, 7-, 8-, 9-, and 10-mm optical zones in the superior, inferior, nasal, temporal, and central areas. The secondary outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, thinnest location value, and keratometry readings.
Results:
A significant improvement in the UDVA and CDVA was observed six months after the surgery (P 0.001) with a significant reduction in the spherical (4.67 diopters (D)) and cylindrical (2.19 D) refractive errors. A significant reduction in the corneal asphericity in all the optical zones and in the superior, inferior, nasal, temporal, and central areas was noted (P 0.001). The mean thickness at the thinnest location of the cornea decreased from 437.15 30.69 to 422.81 36.91 μm. A significant corneal flattening was seen. The K1, K2, and Km changes were 5.32 D, 7 D, and 6.17 D, respectively (P 0.001).
Conclusion:
MyoRing implantation is effective for improving corneal asphericity in patients with KCN. It allows successful corneal remodeling and provides a significant improvement in UDVA, CDVA, and refractive errors.
More Related Videos
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

